AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: LMX 4 Topical Cream
Description: Topical anesthesia cream will be used prior to gene therapy/saline injection.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX 4 Topical Cream
Description: Topical anesthesia cream will be used prior to gene therapy/saline injection.
Study NCT01104207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.
Study NCT01104207 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo rTMS
Description: placebo rTMS
Study NCT02309827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
Study NCT04848948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calory Restriction (F.X. Mayr & VLCD)
Description: VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.
Study NCT04848948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calory Restriction (F.X. Mayr & VLCD)
Description: VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.
Study NCT04848948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.
Study NCT04078048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidants (Vitamin C, E )
Description: For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
Study NCT04078048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidants (Vitamin C, E )
Description: For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
Study NCT04458649 — intervention group
Intervention type: DEVICE
Intervention: Dexcom continuous glucose monitor
Description: Measurement of interstitial glucose
Study NCT01532622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Powder
Description: Patients will take 30 grams of blueberry powder daily for up to 30 days
Study NCT01532622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Patients will take 30 grams of placebo powder daily for up to 30 days.
Study NCT02438878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Behavior
Study NCT02402348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT06193395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: No intervention, only clinical testing of questionnaire
Study NCT02291900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: retrograd drilling of the avascular talar necrosis, followed by osseous autograft
Study NCT01768806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY Project Intervention for Autism
Description: Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
Study NCT01768806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Special education pre-school
Description: Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
Study NCT05906810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study NCT05906810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study NCT01170286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole peanut extract
Description: Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
Study NCT01170286 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo formulation
Description: Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
Study NCT02242292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Study NCT02242292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01701726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
Study NCT01701726 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
Study NCT02490488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Study NCT02490488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02490488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Study NCT02490488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03187678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i.v. selexipag
Description: Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
Study NCT03187678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral selexipag (Uptravi)
Description: Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
Study NCT04315857 — intervention group
Intervention type: OTHER
Intervention: interstitial glycaemia
Description: Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
Study NCT02079753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inogen
Description: single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
Study NCT02079753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination system of a portable and a stationary device.
Description: Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)
Study NCT01399736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR-guided revascularisation strategy
Description: FFR-guided revascularisation strategy
Study NCT01399736 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: randomised to guidelines group
Description: Staged revascularisation by proven ischemia or persistence of symptoms of angina
Study NCT03947138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3107
Description: BCG Vaccine
Study NCT03947138 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal BCG SSI inj.
Description: BCG Vaccine
Study NCT00379340 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Study NCT00379340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Study NCT00379340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00379340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT00379340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00379340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00379340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study NCT01870661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long axis IV placement with ultrasound
Description: Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
Study NCT01870661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short axis IV placement with ultrasound
Description: Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
Study NCT01601197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Description: Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
Study NCT05159609 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Closed loop auditory stimulus
Description: 50ms of low volume pink noise delivered during slow wave sleep
Study NCT05159609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed loop auditory stimulus
Description: 50ms of low volume pink noise delivered during slow wave sleep
Study NCT06371248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steady Feet
Description: Steady Feet is a three-month progressive exercise-based single-component intervention spanning twenty-four sessions, with a focus on enhancing balance, mobility, and strength among community-dwelling older adults at risk of falls.
Study NCT06371248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for fall prevention
Description: CGH's usual care for fall prevention, which include fall prevention materials and advice.
Study NCT06371248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care for fall prevention
Description: CGH's usual care for fall prevention, which include fall prevention materials and advice.
Study NCT00623207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atropine
Description: I.V Atropine 0.5mg up to 2 mg
Study NCT00623207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: I.V Atropine 0.5mg up to 2 mg
Study NCT00658398 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Interactive Computer Program to prevent alcohol misuse.
Description: Interactive Computer Program with questionnaires, video and informations
Study NCT00658398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Computer Program to prevent alcohol misuse.
Description: Interactive Computer Program with questionnaires, video and informations
Study NCT02070237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
Study NCT02183064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Study NCT02183064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Study NCT01941030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System
Description: Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
Study NCT01941030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Angioplasty
Description: Type of balloon selected is driven by preference of the operator.
Study NCT01941030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty
Description: Type of balloon selected is driven by preference of the operator.
Study NCT00489203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: Given orally
Study NCT00489203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00489203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given after transplant
Study NCT00489203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Given after transplant
Study NCT00489203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given after transplant
Study NCT00489203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given after transplant
Study NCT00489203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo stem cell transplant
Study NCT00489203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo stem cell transplant
Study NCT02317237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Description: Conscious sedation
Study NCT02805322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC InstaTemp MD
Description: Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
Study NCT02805322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien Genius 2 Tympanic Thermometer
Description: Measurement of Tympanic Temperature using a standard approved method - Control arm.
Study NCT02805322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Welch Allen SureTemp Plus Sublingual Thermometer
Description: Measurement of Sublingual Temperature using a standard approved method - Control arm.
Study NCT03807141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Description: This is a modified version of the ketogenic diet where-in carbohydrates are restricted without any protein or calorie restriction.
Study NCT03113006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation
Description: Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
Study NCT03113006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation
Description: Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
Study NCT00148564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: treatment with either Olanzapine or Ziprasidone
Study NCT00148564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: treatment with either Olanzapine or Ziprasidone
Study NCT03980288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T Cells
Description: Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
Study NCT02995070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG
Description: Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
Study NCT02995070 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: CTG
Description: Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
Study NCT02995070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
Study NCT02995070 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
Study NCT00290147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Description: IM injection delivered by Biojector
Study NCT01806090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
Study NCT01806090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)
Study NCT00076102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m\^2 every 8 hours (1500 mg/m2/day).
Study NCT00582088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEE C-84
Description: Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer \<1:20.
Study NCT02854280 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedalling exercise on a cycle ergometer
Description: At 80% of the maximal aerobic power, until exhaustion
Study NCT02854280 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Isolated contractions of the quadriceps
Description: Until exhaustion
Study NCT02679183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically-Graded Honey
Description: Honey added to the baby formula once a day for 2 weeks.
Study NCT02679183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Premature Milk Formula
Description: Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
Study NCT02679183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premature Milk Formula
Description: Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
Study NCT03414749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower Extremity First (LEF)
Description: The intervention for the LEF group was a non-specific long-axis distraction to the ankle, knee, and hip or shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
Study NCT03414749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Extremity First (UEF)
Description: The intervention for the UEF group was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
Study NCT02635243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR438544
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study NCT02635243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-glucagon
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study NCT02635243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT02635243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Pharmaceutical form:solution~Route of administration: intravenous